Also categorized in Clinical Research:
A Phase I Study of Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
x hide permanently

Apeiron Announces Publication of Clinical Data with Anti-GD2 Antibody Demonstrating Efficacy in ...

Send Press Releases with GlobeNewswire

VIENNA, Austria, Dec. 18, 2017 (GLOBE NEWSWIRE) -- APEIRON Biologics AG, a company focused on cancer immunotherapy, today announced the publication of a successful clinical study in high-risk neuroblastoma patients in the December issue of mAbs, a prominent journal in the monoclonal ...

Mentions: Antibody Immunotherapy